



Correction: NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances

Dawn Lee¹ · Darren Burns^{1,2} · Ed Wilson¹

© The Author(s) 2024

Correction: PharmacoEconomics – Open
<https://doi.org/10.1007/s41669-024-00490-x>

In the following sentences of the first paragraph of Sect. 3, “pembrolizumab plus ipilimumab” should have been “pembrolizumab plus lenvatinib” (two instances):

“The consequences became apparent in a subsequent multiple technology appraisal (MTA; TA858, 2023), whereby neither nivolumab plus ipilimumab nor the new treatment pembrolizumab plus ipilimumab were found to be cost effective versus cabozantinib. NICE compromised, providing a positive recommendation for pembrolizumab plus ipilimumab if, and only if, nivolumab plus ipilimumab would otherwise be offered.”

The article has now been corrected so the sentences read:

“The consequences became apparent in a subsequent multiple technology appraisal (MTA; TA858, 2023), whereby neither nivolumab plus ipilimumab nor the new treatment pembrolizumab plus lenvatinib were found to be cost effective versus cabozantinib. NICE compromised, providing a positive recommendation for pembrolizumab plus lenvatinib if, and only if, nivolumab plus ipilimumab would otherwise be offered.”

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s41669-024-00490-x>.

✉ Dawn Lee
d.lee7@exeter.ac.uk

¹ PenTAG, University of Exeter Medical School, University of Exeter, St Luke's Campus, Exeter EX1 2LU, UK

² Delta Hat, Long Eaton, UK